Don't ignore those symptoms. Head and neck cancers are far more manageable, and often curable, with less aggressive treatment ...

Immutep's eftilagimod shows a 17.6-month survival benefit in head and neck cancer. Find out how and why IMMP is continuing to ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC).

DelveInsight’s Head and Neck Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

Laryngeal cancer is a serious condition that can impact your ability to speak, swallow and in some cases, breathe. Each year, ...

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck ...

Despite a congressional mandate to expand care for veterans, internal Veterans Affairs messages obtained by ProPublica paint ...

Low-dose computed tomography is more sensitive than chest radiography in detecting lung metastases or second primary lung cancer in patients with HNSCC.